MEDINET Co., Ltd.
Stock Price Chart
2026/09/29 18:54 UpdatedPrice Trend
2026/09/29 18:54 UpdatedPrice & Trading Details
2026/09/29 18:54 UpdatedPRICE
TRADING
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥634M | ¥662M | ¥769M | ¥810M |
| Gross Profit | ¥128M | ¥98M | ¥113M | ¥110M |
| Operating Income | -¥1,333M | -¥1,426M | -¥1,385M | -¥1,445M |
| Pretax Income | -¥1,249M | -¥1,434M | -¥1,273M | -¥1,358M |
| Net Income | -¥1,254M | -¥1,438M | -¥1,277M | -¥1,362M |
| EPS | -¥6.33 | -¥6.65 | - | -¥5.15 |
| Operating Margin | -210.38% | -215.55% | -180.19% | -178.39% |
| Balance Sheet | ||||
| Total Assets | ¥6,078M | ¥5,634M | ¥5,700M | ¥4,254M |
| Total Equity | ¥5,512M | ¥5,044M | ¥5,191M | ¥3,778M |
| Total Liabilities | ¥566M | ¥590M | ¥509M | ¥476M |
| Cash | ¥4,499M | ¥4,396M | ¥4,651M | ¥2,170M |
| Interest-bearing Debt | ¥4M | ¥2M | ¥1M | ¥0M |
| Equity Ratio | 90.69% | 89.52% | 91.07% | 88.80% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,161M | -¥1,264M | -¥1,271M | -¥1,413M |
| Investing CF | -¥20M | ¥3M | ¥65M | -¥565M |
| Financing CF | ¥1,585M | ¥1,158M | ¥1,461M | -¥3M |
| Free CF | -¥1,202M | -¥1,349M | -¥1,331M | -¥1,446M |
| Efficiency | ||||
| ROE | -22.75% | -28.51% | -24.60% | -36.06% |
| ROA | -20.63% | -25.52% | -22.40% | -32.02% |
Latest IR Information
-
Notice on Monthly Exercise Status of the 20th Share Options with Exercise Price Adjustment Provisions issued via Third-Party Allotment
Disclosure of the monthly exercise status for the 20th issue of share options with exercise price adjustment provisions. The number of shares issued since the beginning of the period is 1,000,000 shares; new shares issued due to exercise in August...
Read more -
Notice Regarding Recording of Non-Operating Income
Notification of the outline regarding the recording of non-operating income for the cumulative third quarter of the fiscal year ending September 2026. Specific amounts are unknown.
Read more -
Monthly Exercise Status of the 20th Stock Acquisition Rights (with Exercise Price Adjustment Provisions) Issued to Third Party Allotment
Discloses monthly exercise status of the stock acquisition rights (20th issue, with exercise price adjustment provisions). In July, the number of granted shares was 1,000,000 shares, the exercise ratio to the total issued shares was 1.69%, and unexercised rights decreased...
Read more -
Notice Regarding the Passing of Outside Director
On July 15, 2026, Outside Director Mr. Jo Shinoda passed away and retired as of the same date. The number of directors remains unchanged in accordance with law.
Read more
Latest News (5 items)
Company Information
About
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. It operates through two segments: Cell Processing Business and Regenerative Medicine Products Business.The company's solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy.It also manufactures regenerative medical/investigational and specified cell products. In addition, the company offers value chain solutions, such as personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. The company serves medical institutions, research institutions, and biopharmaceutical companies. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.
